Bipolar Androgen Therapy for Advanced Disease | Mark Scholz, MD | PCRI

Bipolar Androgen Therapy for Advanced Disease | Mark Scholz, MD | PCRI

Testosterone Replacement Therapy For Metastatic #ProstateCancer | #MarkScholzMD #AlexScholz #PCRIПодробнее

Testosterone Replacement Therapy For Metastatic #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI

Promising Studies In Prostate Cancer | A 2021 ASCO Update | Mark Scholz, MDПодробнее

Promising Studies In Prostate Cancer | A 2021 ASCO Update | Mark Scholz, MD

Lutetium-177 and Bipolar Androgen Therapy: Future Game Changers In Prostate Cancer | PCRIПодробнее

Lutetium-177 and Bipolar Androgen Therapy: Future Game Changers In Prostate Cancer | PCRI

OS and biomarker results from COMBAT: bipolar androgen therapy plus nivo for patients with mCRPCПодробнее

OS and biomarker results from COMBAT: bipolar androgen therapy plus nivo for patients with mCRPC

New Study: Hormone Therapy & Heart Disease | Diet & Exercise | Mark Scholz, MD | PCRIПодробнее

New Study: Hormone Therapy & Heart Disease | Diet & Exercise | Mark Scholz, MD | PCRI

Advanced #ProstateCancer Treatments + Extended Q+A | #MarkScholzMD & #MarkMoyadMD #PCRIПодробнее

Advanced #ProstateCancer Treatments + Extended Q+A | #MarkScholzMD & #MarkMoyadMD #PCRI

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRIПодробнее

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRI

Chemo, Hormone Therapy, and Radiation For Advanced Metastatic #ProstateCancer #MarkScholzMD #PCRIПодробнее

Chemo, Hormone Therapy, and Radiation For Advanced Metastatic #ProstateCancer #MarkScholzMD #PCRI

Radiation and Hormone Therapy | Prostate Cancer | Mark Scholz, MD | PCRIПодробнее

Radiation and Hormone Therapy | Prostate Cancer | Mark Scholz, MD | PCRI

Treating High-Risk Gleason 8: A Modern Approach | Mark Scholz, MD | PCRIПодробнее

Treating High-Risk Gleason 8: A Modern Approach | Mark Scholz, MD | PCRI

Testosterone Recovery After Lupron | Answering YouTube Comments #60 | Mark Scholz, MD | PCRIПодробнее

Testosterone Recovery After Lupron | Answering YouTube Comments #60 | Mark Scholz, MD | PCRI

Intermediate-Risk: Do You Need Hormone Therapy With Radiation? | #MarkScholzMD #AlexScholz #PCRIПодробнее

Intermediate-Risk: Do You Need Hormone Therapy With Radiation? | #MarkScholzMD #AlexScholz #PCRI

Characterization of PSA responses to bipolar androgen therapy in mCRPCПодробнее

Characterization of PSA responses to bipolar androgen therapy in mCRPC

Clinical Trial: Car-T Cell Therapy for Prostate Cancer | Mark Moyad, MD, MPH & Mark Scholz, MDПодробнее

Clinical Trial: Car-T Cell Therapy for Prostate Cancer | Mark Moyad, MD, MPH & Mark Scholz, MD

Hormone Therapy Side Effect Solutions: Exercise, Acupuncture, and More | Mark Moyad, MD | PCRIПодробнее

Hormone Therapy Side Effect Solutions: Exercise, Acupuncture, and More | Mark Moyad, MD | PCRI

Comparing the Second Generation Hormone Therapies | Ask a Prostate Expert, Mark Scholz, MDПодробнее

Comparing the Second Generation Hormone Therapies | Ask a Prostate Expert, Mark Scholz, MD

The TRANSFORMER Study: Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With mCRPCПодробнее

The TRANSFORMER Study: Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With mCRPC

High Testosterone, Exercise, & Prostate Cancer | Answering YouTube Comments | Mark Scholz, MD | #16Подробнее

High Testosterone, Exercise, & Prostate Cancer | Answering YouTube Comments | Mark Scholz, MD | #16

PSA Recurrence: When Should You Treat? | Ask a Prostate Expert, Mark Scholz, MDПодробнее

PSA Recurrence: When Should You Treat? | Ask a Prostate Expert, Mark Scholz, MD

New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRIПодробнее

New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRI

Актуальное